Use of amifostine in the therapy of osteosarcoma in children and adolescents

Página do item simplificado
dc.contributor.authorPetrilli, Antonio Sergio [UNIFESP]
dc.contributor.authorOliveira, Delma Tostes [UNIFESP]
dc.contributor.authorGinani, Valéria Cortez [UNIFESP]
dc.contributor.authorKechichian, Rita [UNIFESP]
dc.contributor.authorDishtchekenian, Andrea [UNIFESP]
dc.contributor.authorRoque Filho, Werthon de Medeiros [UNIFESP]
dc.contributor.authorTanaka, Cristiana [UNIFESP]
dc.contributor.authorDias, Carlo Gonçalves [UNIFESP].
dc.contributor.authorLatorre, Maria do Rosário Dias de Oliveira
dc.contributor.authorBrunetto, Algemir Lunardi
dc.contributor.authorCardoso, Hedilene
dc.contributor.authorAlmeida, Maria Teresa
dc.contributor.authorCamargo, Beatriz de
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHosp Clin Porto Alegre
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2016-01-24T12:33:18Z
dc.date.available2016-01-24T12:33:18Z
dc.date.issued2002-03-01
dc.description.abstractAmifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. in this study. 39 consecutive newly diagnosed children with osteosarcoma were assessed; 20 received amifostine and 19 did not. the chemotherapy regimen included an induction phase of three cycles of cisplatin (100 mg/m(2)), carboplatin (500 mg/m(2)), and doxorubicin (60 mg/m(2)), followed by surgery. Alternating cycles of cisplatin/ifosfamide (9 mg/m(2)), ifosfamide/doxorubicin. carboplatin/doxorubicin, and ifosfamide/carboplatin were administered every 3 weeks to complete 26 weeks of treatment. Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. Side effects during infusions and renal, hearing, and bone marrow toxicities were evaluated and compared between the two groups. Hypotension was observed in 28 (14.5%) infusions. No patient required discontinuation of therapy. Fewer than two episodes of vomiting occurred in 130 (71%) infusions and two to five episodes occurred in 51 (28%) infusions. and no patient had grade 4 toxicity. There was no difference between the two groups regarding renal toxicity (creatinine clearance). Neutropenia and leukopenia were significantly less frequent in the amifostine group. No difference was observed in platelet and hearing toxicities. Amifostine was well tolerated in doses of 740 mg/m(2) in children and adolescents, and myelotoxicity was less severe in the amifostine group. This was a pilot study for further evaluation in a larger randomized trial.en
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pediat, Pediat Oncol Inst, São Paulo, Brazil
dc.description.affiliationAC Camargo Hosp, Dept Pediat, São Paulo, Brazil
dc.description.affiliationHosp Clin Porto Alegre, Dept Pediat, Porto Alegre, RS, Brazil
dc.description.affiliationUniv São Paulo, Childrens Inst, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Coll Publ Hlth, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Human Commun Disorders Orhorrinolaringol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pediat, Pediat Oncol Inst, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Human Commun Disorders Orhorrinolaringol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent188-191
dc.identifierhttps://dx.doi.org/10.1097/00043426-200203000-00006
dc.identifier.citationJournal of Pediatric Hematology Oncology. Philadelphia: Lippincott Williams & Wilkins, v. 24, n. 3, p. 188-191, 2002.
dc.identifier.doi10.1097/00043426-200203000-00006
dc.identifier.issn1077-4114
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/26796
dc.identifier.wosWOS:000174910300005
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Pediatric Hematology Oncology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAmifostineen
dc.subjectChildren and adolescentsen
dc.subjectOsteosarcomaen
dc.titleUse of amifostine in the therapy of osteosarcoma in children and adolescentsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos